Vikas Yadav

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 15

Top Venues

Cancers

Pharmaceutical patent analyst

Exploration of targeted anti-tumor therapy

Briefings in functional genomics

LUNDS UNIVERSITET

CSIR-IGIB / JAMIA HAMDARD (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

LUNDS UNIVERSITET Sep 01 2019

Sweden

Postdoctoral Fellow :: Department of Translational Medicine

UNIVERSITY DE LIEGE Jun 01 2017 - Aug 30 2019

Belgium

POSTDOCTORAL FELLOW :: GIGA

CSIR-IGIB (Institute of Genomics and Integrative Biology) Oct 01 2015 - May 21 2017

India

RESEARCH ASSOCIATE :: Functional Genomics Unit

Education History

CSIR-IGIB / JAMIA HAMDARD Nov 10 2010 - Nov 09 2016

India

PHD :: Functional Genomics Unit

Publications

Tejveer Singh, Deepika Sharma, Rishabh Sharma, Hardeep Singh Tuli, Shafiul Haque, Seema Ramniwas, Darin Mansor Mathkor, Vikas Yadav
The Role of Phytonutrient Kaempferol in the Prevention of Gastrointestinal Cancers: Recent Trends and Future Perspectives. Cancers 16 (9) (2024)
Tejveer Singh, Deepika Sharma, Rishabh Sharma, Hardeep Singh Tuli, Shafiul Haque, Seema Ramniwas, Darin Mansor Mathkor, Vikas Yadav
The Role of Phytonutrient Kaempferol in the Prevention of Gastrointestinal Cancers: Recent Trends and Future Perspectives. Cancers 16 (9) (2024)
Abhilasha Sood, Arpit Mehrotra, Ujjawal Sharma, Diwakar Aggarwal, Tejveer Singh, Moyad Shahwan, Ammar Abdulrahman Jairoun, Isha Rani, Seema Ramniwas, Hardeep Singh Tuli, Vikas Yadav, Manoj Kumar
Advancements and recent explorations of anti-cancer activity of chrysin: from molecular targets to therapeutic perspective. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Ravinder Sharma, Kiran Yadav, Leeza Monga, Vikas Gupta, Vikas Yadav
Identification of pivotal genes and pathways in Chorea-acanthocytosis using comprehensive bioinformatic analysis. PloS one 19 (9) (2024)
Abhilasha Sood, Arpit Mehrotra, Ujjawal Sharma, Diwakar Aggarwal, Tejveer Singh, Moyad Shahwan, Ammar Abdulrahman Jairoun, Isha Rani, Seema Ramniwas, Hardeep Singh Tuli, Vikas Yadav, Manoj Kumar
Advancements and recent explorations of anti-cancer activity of chrysin: from molecular targets to therapeutic perspective. Exploration of targeted anti-tumor therapy 5 (3) (2024)
Palak Rani, Vikas Yadav, Parijat Pandey, Kiran Yadav
Recent patent-based review on the role of three-dimensional printing technology in pharmaceutical and biomedical applications. Pharmaceutical patent analyst (2023)
Hardeep Singh Tuli, Mükerrem Betül Aycan, Vikas Yadav
Cancer and Nutrients. Cancers 15 (16) (2023)
Manoj Kumar Jena, Farheen Badrealam Khan, Syed Azmal Ali, Abdullah Abdullah, Amarish Kumar Sharma, Vikas Yadav, Sudhakar Kancharla, Prachetha Kolli, Gowtham Mandadapu, Anjan Kumar Sahoo, Prasana Kumar Rath, Jalal Taneera, Sudarshan Kumar, Ashok Kumar Mohanty, Khang Wen Goh, Long Chiau Ming, Chrismawan Ardianto
Molecular complexity of mammary glands development: a review of lactogenic differentiation in epithelial cells. Artificial cells, nanomedicine, and biotechnology 51 (1) (2023)
Vikas Yadav, Srividhya Ravichandran
Significance of understanding the genomics of host-pathogen interaction in limiting antibiotic resistance development: lessons from COVID-19 pandemic. Briefings in functional genomics (2023)
Vikas Yadav, Amarish Kumar Sharma, Gaurav Parashar, Nidarshana Chaturvedi Parashar, Seema Ramniwas, Manoj Kumar Jena, Hardeep Singh Tuli, Kiran Yadav
Patent landscape highlighting therapeutic implications of peptides targeting myristoylated alanine-rich protein kinase-C substrate (MARCKS). Expert opinion on therapeutic patents (2023)
Vikas Yadav, Rubina Islam, Hardeep Singh Tuli
Patent landscape highlighting double-edged scaffold of a WNT5A-agonizing peptide, Foxy5. Pharmaceutical patent analyst (2023)
Vikas Yadav, Njainday Jobe, Shakti Ranjan Satapathy, Purusottam Mohapatra, Tommy Andersson
Increased MARCKS Activity in BRAF Inhibitor-Resistant Melanoma Cells Is Essential for Their Enhanced Metastatic Behavior Independent of Elevated WNT5A and IL-6 Signaling. Cancers 14 (24) (2022)
Vikas Yadav, Njainday Jobe, Shakti Ranjan Satapathy, Purusottam Mohapatra, Tommy Andersson
Increased MARCKS Activity in BRAF Inhibitor-Resistant Melanoma Cells Is Essential for Their Enhanced Metastatic Behavior Independent of Elevated WNT5A and IL-6 Signaling. Cancers 14 (24) (2022)
Hardeep Singh Tuli, Prangya Rath, Abhishek Chauhan, Katrin Sak, Diwakar Aggarwal, Renuka Choudhary, Ujjawal Sharma, Kanupriya Vashishth, Sheetu Sharma, Manoj Kumar, Vikas Yadav, Tejveer Singh, Mükerrem Betül Aycan, Shafiul Haque
Luteolin, a Potent Anticancer Compound: From Chemistry to Cellular Interactions and Synergetic Perspectives. Cancers 14 (21) (2022)
Purusottam Mohapatra, Vikas Yadav, Maren Toftdahl, Tommy Andersson
WNT5A-Induced Activation of the Protein Kinase C Substrate MARCKS Is Required for Melanoma Cell Invasion. Cancers 12 (2) (2020)

Vikas Yadav.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Vikas Yadav